News

The Search for Ingredients to Replicate Silicon Valley

Tuesday, March 22, 2011

By STEVEN M. DAVIDOFF 

PharmaJet is Granted FIRST-EVER FDA Clearance

Tuesday, March 22, 2011

FDA Grants PharmaJet® 510(k) Clearance on Intradermal Needle-free Injection Device
First FDA-cleared needle-free injection alternative to needle-based "Mantoux" method. 

Colorado Used Lab Equipment for Sale, Extronex Inc.

Monday, March 21, 2011

EXTRONEX, INC.
Equipment Remarketers - Putting Buyers And Sellers Together Since 1996 

Now Excepting Applications for 2011 Governor’s Award for Excellence in Exporting

Thursday, March 10, 2011

Colorado Office of Economic Development & International Trade Now Excepting Applications for 2011 Governor’s Award for Excellence in Exporting 

Biotechs progressing toward goals

Tuesday, March 08, 2011

BOULDER — A handful of area biotechnology firms are moving full steam ahead, bucking a national trend that has seen many cash-strapped companies in the field close down for lack of funding.

Those companies include Boulder-based AmideBio LLC, which is creating new, natural material which could revolutionize Alzheimer's research. Boulder-based miRagen Therapeutics Inc. recently received a key U.S. Food and Drug Administration approval for a drug to regulate blood cell development. And Boulder-based InDevR Inc. saw its virus research published in an important industry journal.

More than 80 bioscience companies large and small are located in the Boulder Valley, according to the Colorado BioScience Association. Of those, 35 are biotech/pharmaceutical companies, 40 are medical device companies, and at least four are biofuel companies. Bioscience workers make an average salary of $74,000, according to state statistics.  

Clarimedix presents findings

Monday, March 07, 2011

Treatment Targets Alzheimer's Symptoms with Non-Invasive, Non-Drug Device  

VetDC wins Entrepreneurial Challenge

Monday, March 07, 2011

Winners announced in UNC Entrepreneurial Challenge  

St. Renatus announces favorable FDA review

Monday, March 07, 2011

St. Renatus, LLC (Fort Collins) announced that the company had a favorable End of Phase 2 review with the U.S. Food and Drug Administration (FDA), and agreed that in the near future, the company will proceed with conducting Phase 3 efficacy studies to determine the exact parameters for their nasal mist dental anesthetic achieving dental anesthesia in the maxillary arch.  St. Renatus and the FDA discussed details for both Phase 3 Adult and Pediatric studies to be conducted in the near future. Final revised protocols will be forwarded to the FDA in the coming weeks.  

CaridianBCT to be sold for $2.6B

Monday, March 07, 2011

(Reuters) - Terumo Corp (4543.T) said it would buy U.S. medical device company CaridianBCT from a Swedish firm for about $2.6 billion, marking the largest acquisition by a Japanese medical equipment maker. 

N30 Pharmaceuticals to Present Preclinical Data

Thursday, March 03, 2011

N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting.